Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Scheinberg

Showing results (11-20 of 172) with videos related to

Pageof 18
Sort By:
Nature Clinical Practice. Oncology|May 10, 2006
Antibody-drug conjugates in acute myeloid leukemiaDavid A Scheinberg, Joseph G Jurcic, Peter Maslak
Advanced Drug Delivery Reviews|June 3, 2008
Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applicationsMatthias Miederer, David A Scheinberg, Michael R McDevitt
Plos One|November 17, 2012
Dysregulation of IRP1-mediated iron metabolism causes gamma ray-specific radioresistance in leukemia cellsKurtis J Haro, Aneesh Sheth, David A Scheinberg
Blood|July 26, 2012
Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cellsKurtis J Haro, Andrew C Scott, David A Scheinberg
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
The promise of targeted {alpha}-particle therapyDeborah A Mulford, David A Scheinberg, Joseph G Jurcic
Cancer Control : Journal of the Moffitt Cancer Center|April 20, 2002
Radioimmunotherapy for acute leukemiaJohn M Burke, Joseph G Jurcic, David A Scheinberg
Assay and Drug Development Technologies|July 28, 2010
A high-throughput screen for alpha particle radiation protectantsJonathan H Seideman, David Shum, Hakim Djaballah, et al.
Hematology. American Society of Hematology. Education Program|November 25, 2004
Immunotherapeutic approaches for hematologic malignanciesMichael A Caligiuri, Andrea Velardi, David A Scheinberg, et al.
Seminars in Hematology|February 4, 2003
Novel targeted and immunotherapeutic strategies in chronic myeloid leukemiaJoseph Schwartz, Javier Pinilla-Ibarz, Rui Rong Yuan, et al.
Haematologica|October 13, 2005
Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responsesJavier Pinilla-Ibarz, Tatyana Korontsvit, Victoriya Zakhaleva, et al.
Pageof 18

Showing results (11-20 of 172) with videos related to

Sort By:
Pageof 18
Nature Clinical Practice. Oncology|May 10, 2006
Antibody-drug conjugates in acute myeloid leukemiaDavid A Scheinberg, Joseph G Jurcic, Peter Maslak
Advanced Drug Delivery Reviews|June 3, 2008
Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applicationsMatthias Miederer, David A Scheinberg, Michael R McDevitt
Plos One|November 17, 2012
Dysregulation of IRP1-mediated iron metabolism causes gamma ray-specific radioresistance in leukemia cellsKurtis J Haro, Aneesh Sheth, David A Scheinberg
Blood|July 26, 2012
Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cellsKurtis J Haro, Andrew C Scott, David A Scheinberg
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
The promise of targeted {alpha}-particle therapyDeborah A Mulford, David A Scheinberg, Joseph G Jurcic
Cancer Control : Journal of the Moffitt Cancer Center|April 20, 2002
Radioimmunotherapy for acute leukemiaJohn M Burke, Joseph G Jurcic, David A Scheinberg
Assay and Drug Development Technologies|July 28, 2010
A high-throughput screen for alpha particle radiation protectantsJonathan H Seideman, David Shum, Hakim Djaballah, et al.
Hematology. American Society of Hematology. Education Program|November 25, 2004
Immunotherapeutic approaches for hematologic malignanciesMichael A Caligiuri, Andrea Velardi, David A Scheinberg, et al.
Seminars in Hematology|February 4, 2003
Novel targeted and immunotherapeutic strategies in chronic myeloid leukemiaJoseph Schwartz, Javier Pinilla-Ibarz, Rui Rong Yuan, et al.
Haematologica|October 13, 2005
Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responsesJavier Pinilla-Ibarz, Tatyana Korontsvit, Victoriya Zakhaleva, et al.
Pageof 18